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bhis review covers the time period July 2008 to June 2009
ith 1 exception.
ortic Valve Stenosis (AS)
udden death in young athletes. A total of 1,866 athletes,
ge 19  6 years, died suddenly or survived cardiac arrest in
he U.S. from 1980 to 2006. At autopsy, 690 deaths due to
ardiovascular (CV) events were confirmed; AS was the only
bnormality found in 19 (2.8%) (1).
OMMENT. This study documents that sudden death
ccurs in young people with AS. The frequency and
ncidence of sudden death and of AS cannot be deter-
ined from this study.
tiological considerations. a) Endothelium was found to
lay a role in regulating the mechanical properties of aortic
alve (AV) cusps, emphasizing valve cellular integrity for
ptimal valve function (2).
b) Valve cusps show increased thermal heterogeneity in
S versus those in aortic regurgitation (AR), which
orrelated with inflammatory mononuclear cell infiltra-
ion, proinflammatory cytokines, and neoangiogenic fac-
ors (3).
c) Oxidative stress is increased in calcified regions of
alves in AS (4). Increased oxidative stress is partly due to
eduction in expression and activity of antioxidant enzymes
nd possibly to uncoupled nitric oxide synthases. Mecha-
isms of oxidative stress are different in AS and atheroscle-
otic arteries (Fig. 1).
OMMENT. The same group reported that rapid normal-
zation of elevated cholesterol had beneficial effects (5).
d) Rapid normalization of elevated cholesterol levels by
nducing expression of Cre recombinase in hypercholester-
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009; accepted February 1, 2010.lemic Reversa mice with early AV disease (AVD) normal-
zes oxidative stress, reduces pro-osteogenic signaling, and
alts the progression of AS (Fig. 2) (5).
e) Senescence of valvular endothelial cells reduces its
egenerative capacity and decreased levels of endothelial
rogenitor cells are partly a pathological link for the de-
truction of valvular endothelial cells, which results in the
rogression of calcific AS (6).
f) A strong association was established (7) between AS
nd aortic atherosclerosis (AA) that was independent of age
nd sex. The prevalence of severe AA increased across
rades of AS; 57% of patients had severe AS and severe AA.
troke volume (SV) measurement by real-time 3-dimensional
chocardiography (RT3DE) is more accurate than by
-dimensional echocardiography (2DE). In 68 patients
ith AS, age 74 12 years, RT3DE color Doppler imaging
nd 2DE were performed (8). Correlation between AV area
AVA) by 2DESV and AVA3D-SV was modest, (r  0.71,
 0.001; mean difference 0.11  0.23 cm2) (Fig. 3). In a
ubgroup of 38 cases, AVA3D-SV had better agreement with
VA3D-Pl (Pl  planimetry) than AVA2D (mean differ-
nce  0.001  0.15 cm2 vs. 0.10  0.26 cm2, p 
.038). Cardiac output and SV measurements were vali-
ated against flow probes in experimental sheep with a
istorted left ventricular (LV) outflow tract; 3DE was
learly superior to 2 DE (Fig. 4).
OMMENT. Measurements from LV outflow tract for SV
nd AVA calculations can be very difficult with 2DE, which
s well-known to most clinical echocardiographers/
linicians. Studies in humans that measure a range of SV
imultaneously with 3DE and an independent technique are
eeded. Please see RT3DE in mitral regurgitation, which
ocuments better assessment of severity of mitral regurgi-
ation (MR) compared with 2DE. RT3DE provides a much
etter assessment of severe aortic and mitral valve disease
MVD).
ontribution of the arterial system to response with
xercise. Eighteen patients with AS included in the study
ere age 60  8 years, LV ejection fraction (LVEF) was
0.55 by angiography and had no significant AR or
bstructive coronary artery disease (CAD). Using high-
delity catheter recordings of ascending aortic pressure and
lood flow velocity at rest (9), systemic vascular resistance,
rterial elastance, and aortic characteristic impedance were
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Year in Valvular Heart Disease April 20, 2010:1729–42ncreased in patients with AS compared with 11 controls. In
ontrast, total arterial compliance was lower compared with
ontrols (0.737  0.19  103 cm5/dyne vs. 1,155  0.27
103 cm5/dyne, p  0.001). With exercise, total arterial
Figure 1 Mechanisms Generating
Oxidative Stress in Plaques and Valves
Mechanisms generating oxidative stress are different in calcified aortic valve
stenosis and atherosclerotic plaques. ↔  no change; /  increases or
decreases have been reported; NADPH  nicotinamide adenine dinucleotide
phosphate; NOS  nitric oxide synthase. Reproduced with permission from
Miller et al. (4).
Figure 2 Beneficial Effects of Normalization of Blood Lipids
Lipid (red staining) in aortic valves of mice. (A, B) 6- and 12-month control mice. (
12 months. Arrows indicate aortic valve tissue. *p  0.05 versus time-matched cont
mission from Miller et al. (5).ompliance increased in controls but did not change in those
ith AS. Arterial elastance increased on exercise, and aortic
haracteristic impedance remained elevated. Stroke flow
ncreased in those with AS and controls but to a much lower
xtent in those with AS (controls: from 230  37 ml/s to
06 69 ml/s, p 0.001; AS: from 229 69 ml/s to 256
6- and 12-month hypercholesterolemic (Hchol) mice. (E) Mice reversed
 0.05 versus 12-month hypercholesterolemic mice group. Reproduced with per-
Figure 3 AVA by 2D and 3D Echocardiography
Scatterplot of correlation between aortic valve area (AVA) calculated from
stroke volume (SV) obtained by 2-dimensional (2D) and 3-dimensional (3D) SV
echocardiogram. Dashed lines represent 95% prediction band of the regression
line. R Sq  Pearson’s correlation coefficient. Reproduced with permission
from Poh et al. (8).C, D)
rols; #p
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April 20, 2010:1729–42 Year in Valvular Heart Disease8 ml/s, p  0.01). On multivariate regression, the increase
n stroke flow was related to decreases in systemic vascular
esistance (p 0.03) and arterial elastance (p 0.02) but an
ncrease in total arterial compliance (p  0.03).
OMMENT. This is a sophisticated study. Properties of the
rterial system distal to the AV directly influence the hemo-
ynamic response to exercise in AS. One thus has to be careful
bout interpretations and clinical implications of data obtained
rom simplistic approaches to exercise tests in AS.
s exercise stress echocardiography (ESE) of additive
alue to exercise tests (ETs)? The added value and clinical
tility of ESE to ETs were evaluated in 101 asymptomatic
atients, 59 men, age 69 10 years, with severe AS (AVA1
m2 or mean gradient50 mmHg) and “normal” LV systolic
unction (10). The ET was a symptom-limited treadmill test
sing the modified Bruce protocol in 80%, and Bruce modified
r manual protocol was applied in the remaining patients.
otal exercise time was 5.24  2.6 min and workload was 6.5
2.4 metabolic equivalents. The ET was abnormal in 69
68%) patients; symptoms developed in 48 patients. An abnor-
al blood pressure response was the only abnormality in 24
atients. An abnormal “contractile response” was observed in
2 patients, and in 7 of these patients, this was the only
bnormal parameter; 10 of these 12 patients had coronary
rteriography and significant coronary stenosis was present in 7.
OMMENT. ESE provided additional information for ETs
n 12 of 101 patients. However, the treadmill ET is not
ptimal for ESE because there is a 1- to 2-min delay
etween the end of the test and the beginning of acquisition
f adequate echocardiographic data during which time
eriod, that is, at the end of the ET, there is a very rapid
efervescence of the cardiac response. Previously Marechaux
t al. (11) described a decline in LVEF by echocardiography in
0% of patients undergoing a supine bicycle test; in the present
Figure 4 CO Obtained From 2DE and 3DE Versus That From Flo
Cardiac output (CO) by stroke volume obtained from left ventricular outflow tract (L
and 3-dimensional echocardiogram (3DE) (right) versus that obtained from flow prtudy, LVEF was not measured and visual estimate of LV aunction documented the additional value in very few patients.
n the age group of this study, 50% of patients can be
xpected to have associated CAD (12). In the absence of
nowledge about associated CAD, one does not know whether
he abnormal ET/ESE is due to AS and/or CAD.
he much-awaited SEAS trial results: negative for AS.
he SEAS (Simvastatin and Ezetimibe Aortic Stenosis)
rial is a randomized, double-blind trial in 1,873 asymptom-
tic patients with mild to moderate AS (13). During a
edian follow-up of 52.2 months, there was no statistically
ignificant difference in “primary outcome” (a combination
f 9 different events) between the simvastatin-ezetimibe
roup (35.3%) and the placebo group (38.2%) (p  0.59).
here was no significant difference in performance of AVR
p  0.97); however, there were fewer incidents of ischemic
V events in the treated group (p  0.02), mainly because
ewer patients underwent coronary artery bypass graft
CABG). The incidence of cancer was greater (p  0.01).
OMMENT. The clinical validity of this last observation has
een questioned.
xcellent 30-month outcome after AVR for severe AS in
elected subgroups. The 30-day mortality of 6,369 pa-
ients in New York State from 2003 to 2005 was 3.97% for
solated AVR (n 3,327, age 68.9 13.4 years) and 5.69%
or AVR  CABG (n  3,042, age 64.2  8.9 years) (14).
wo subgroups had particularly notable results at 30-month
ollow-up: in patients 75 years of age and older who had AVR
ABG, the risk-adjusted survival rate of 83.3% was not
ignificantly different from the rate of 84.0% of age- and
ex-matched patients in the population and 64.3% of patients
ith isolated AVR (who did not have heart failure [HF],
VEF 0.40, acute myocardial infarction 24 h, or hemo-
ynamic instability) had a risk-adjusted survival rate of 89.9%,
hich was statistically equivalent to the 90% survival rate of an
obes
n 2-dimensional echocardiogram (2DE) (left)
Reproduced with permission from Poh et al. (8).w Pr
VOT) i
obes.ge- and sex-matched population.
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atrogenic AR. Percutaneous transcatheter closure was
eemed successful in 89% of 70 patients with ASD and in
2% of 170 patients with a patent foramen ovale (15). At
ollow-up of 27  15 months, the “overall major” compli-
ation rate was 0.8%. Transesophageal echocardiography
TEE) at 3, 6, and 12 months showed newly developed or
orsened AR in 9% of those with ASD and in 10% of those
ith a patent foramen ovale, which was “independent” of
ge, sex, or size of defect. The authors speculated that a
potential cause for developing AR may be overgrowth of
he device by tissue, leading to changes in the interatrial
eptal geometry and traction on the root of the non-
oronary aortic cusp” (Fig. 5).
OMMENT. This complication is in addition to other com-
lications (16).
echanism of functional AR (FAR) in ascending tho-
acic aortic aneurysm (ATAA) with a normal AV. A total
f 89 patients with ATAA, age 59  13 years, with varying
egrees of FAR were studied. Surgery was performed for
TAA with an aortic diameter of 50 mm and a normal
V (17). There were 2 control groups: 40 age-matched
atients with ATAA and no FAR and 20 age- and
ex-matched subjects without heart disease. Severity of AR
as graded by vena contracta (VC) width on TEE; VC
idth was 5.59  2.59 mm. Various parameters were
nalyzed. FAR was caused by diastolic tenting of AV leaflets
Fig. 6). On multivariate analysis, the most strongly asso-
iated with FAR was the severity of diastolic leaflet tenting;
ts coaptation height 1.1 cm had 98% sensitivity and 95%
pecificity. The mismatch of the dimension of sinotubular
unction and annulus determined the severity of tenting and
f AR; its ratio of 1.66 had 98% sensitivity of and 95%
pecificity.
Figure 5 ASD Closure and Aortic Regurgitation
Schematic parasternal short-axis view of atrial septal defect (ASD) (left). Shrinkag
explanation for production of aortic regurgitation. LA  left atrium; NCC  noncoroicuspid AV (BAV)
utcomes in adults. In 642 patients, age 35  16 years,
he 10-year survival was 96  1% (18). Primary cardiac
vents occurred in 25  2%, which included death in 3 
%, valve or aorta intervention in 22 2%, aortic dissection
n 2  1%, and HF in 2  1%. Independent predictors of
vents were age older than 30 years and moderate or severe
S or AR (Fig. 7).
ortopathy in patients with BAV. a) Decreased metallo-
hionein in AA aneurysm. Microarray analysis of 50 aortic
amples (22,000 probe sets) identified 110 dysregulated
enes in BAV compared with tricuspid AV and control
onors; 8 were genes of the metallothionein family (19).
etallothionein gene expression and protein expression
ere significantly lower in aortic tissue and cultured aortic
mooth cells from BAV patients compared with control
ubjects. Matrix metalloproteinase-9 expression was in-
reased in BAV samples. The authors concluded that the
ysregulated metallothionein expression may “contribute to
n inadequate response to oxidative stress and provoke
neurysm formation.”
b) Increased prevalence in relatives of patients with BAV.
his was a study of 48 first-degree relatives (FDRs) of 54
AV patients and 45 control patients. Aortic root dilation
as present in 32% of FDRs, 53% in BAV patients and
one in the control group (20). FDRs and BAV patients
ad significantly lower aortic distensibility (p  0.001) and
greater aortic stiffness index (p  0.001) compared with
ontrols. This difference remained significant in subjects
ithout aortic root dilation (p  0.002) or hypertension
p  0.004).
OMMENT. I recommend FDRs of patients with BAV to
ndergo screening transthoracic echocardiography (TTE)
or assessment of AA and the AV and, if necessary,
dditional testing, for example, TEE.
teratrial septum by ASD occluder (right) may be one
inus; RA  right atrium. Reproduced with permission from Schoen et al. (15).e of in
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merican Heart Association scientific statement. For
he prevention of rheumatic fever and diagnosis and treat-
ent of acute streptococcal pharyngitis (21), this is an
pdate.
t the time of intervention for MVD, the rate of
rogression of associated mild AVD is very slow. A total
f 200 patients (age 30.3  9.9 years; 146 women, 54 men)
ad interventional therapy for rheumatic MVD and were
ollowed for 9.3  1.07 years to evaluate the development of
VD or progression of AVD (group I, n 98). Initially, only
V thickening was present in 16 (group IIA), isolated AR was
resent in 69 (group IIB), and mixed AS/AR in 17 (group
IC) (22). Two patients progressed to severe AS frommild AS
t baseline, necessitating AVR. Of 98 patients, new AVD
eveloped in 10. Mild AR developed in 11 of 16 patients in
roup IIA, andmild AS/AR developed in 1; mild AS andmild
r moderate AR developed in 22 (31.9%) of 60 patients in
roup IIB; 8 of 16 in group IIC progressed to AS, moderate in
Figure 6 Mechanism of FAR in ATAA
(A,B) Transesophageal echocardiograms showing long-axis view of aortic valve and
ascending thoracic aorta aneurysm (ATAA). Functional aortic regurgitation (FAR)
results from tenting of aortic valve. Dotted arrow indicates coaptation height (CH);
tented area (arrowhead) was 1.9 cm2; CH was 1.2 cm and STJ/A ratio was 2.3.
A  aortic annulus; STJ  sinotubular junction; TT  tubular tract; VS  Valsalva
sinuses. Reproduced with permission from La Canna et al. (17).and severe in 2. Thus, severe AVD rarely developed inatients with no or mild AVD, and they rarely (1%) required
V surgery over long-term follow-up.
OMMENT. Important data. The authors reviewed theirs
nd 3 other similar studies in the literature. In the 4 studies
22–25), of 890 patients, severe AVD that needed interven-
ion developed in 19 (0.022%). An editorial accompanying
he first of those articles had strongly recommended against
rophylactic AVR for mild AS (26).
tatins delay progression of rheumatic AS. A retrospec-
ive review of patients, age 61  10 years, whose echocar-
iographic results were typical for rheumatic AS and MVD
nd who had at least 2 echocardiograms 2 years apart
ielded 30 patients who had received statins and 134 who
ad not received such therapy. The progression rate of AS
as judged by changes in peak aortic velocity (27). The
rogression rate in those treated with statins versus not
reated was 0.05  0.07 m/s/year versus 0.12  0.11
/s/year (p  0.001). In the investigators’ laboratory, the
nterobserver coefficient of reproducibility for recording and
easuring peak aortic velocity was 0.20 m/s.
OMMENT. The excellent accompanying editorial (28) pro-
ides a thorough and critical review of the study.
egree of commissural opening of MS with catheter
alloon commissurotomy (CBC) influences long-term
utcome. A total of 875 patients, age 48  13 years, 83%
emale and 75% in New York Heart Association functional
lass III/IV, had “good” immediate results with CBC
mitral valve area [MVA]1.5 cm2 and noMR2/4) (29).
atients were divided into 3 groups: group 1 (n  189),
oth commissures were partially opened or not split; group
(n  489) 1 commissure split; group 3 (n  227), both
ommissures completely split. The MVAs after CBC in the
groups were 1.77  0.19 cm2, 1.93  0.25 cm2, and 2.10
Figure 7 Cardiac Events in Adults With Bicuspid Aortic Valves
Events at 10 years. In all participants, 25  2%; with no risk factors, 6  2%; with
1 risk factor, 18  3%; and with 1 risk factor, 65  5%. Reproduced with permis-
sion from Tzemos et al. (18).
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Year in Valvular Heart Disease April 20, 2010:1729–420.27 cm2, respectively (p  0.0001). On follow-up to 10
ears, patient outcomes were best in group 3 and better in
roup 2 than in group 1. The authors stated “either the
egree of CO (commissural opening) or the MVA was an
ndependent predictor of good late functional results (p 
.05),” but data on MVA were not presented.
OMMENT. This study shows: a) the mechanism of im-
rovement of MS is the extent of commissural opening; and
) the feasibility of evaluating the extent of commissural
pening. This can be vividly seen with use of 3-dimensional
chocardiography in the accompanying editorial (30). Data
n the additional clinical value/benefit of determining
ommissural opening over the measurement of MVA is
mportant and would have been valuable.
Over the past 20 years, data collected worldwide includ-
ng data from these investigators had shown that the larger
he MVA was after CBC, the better was the patient
utcome. From studies of surgical mitral commissurotomy,
t has been known for 50 years that the increase in MVA
s dependent on the extent of commissural opening; there-
ore, the procedure should be labeled as commissurotomy
nd not as a valvuloplasty.
itral Regurgitation
ariability in the assessment of MR. a) Intraobserver
ariability. Twelve “fully qualified echocardiographers” who
routinely and regularly analyze the severity of MR in a
linical setting” at 3 prominent institutions in London,
ngland, participated in the study (31). One (8%) of the 12
bservers gave consistent gradings for the triply presented
mages. Percentages of reporters demonstrating variability
n 1 of 6 cases of one-half of 1 grade (i.e., moderate to
oderate-severe) ranged from 25% to 67%, that of 1 full
rade ranged from 17% to 50%, and that from severe to not
evere or from nonsevere to severe ranged from 8% to 33%.
he investigators concluded the “even a skilled observer
annot be relied upon to give an identical grading to an
dentical sample video clip of MR, when re-presented
urreptitiously within a few minutes.”
OMMENT. This study highlights the need to develop
mproved and better standardized measurements of the
everity of MR.
b) Variations in calculations of mitral regurgitant SV
MRSV). In 73 patients with MR of various etiologies,
RSV was calculated from an apical 4-chamber view using
hemispheric PISA methods (32). Magnetic resonance
maging was used as the reference method. “Single-point
ISA methods yielded greater underestimation of MRSV
or PISA—VTI: 13.3  10.2 ml, for simplified PISA:
3.5  10.3 ml particularly in functional MR, compared
ith time-integral PISA methods accounting for variations
f mitral regurgitant flow rate (MRFR) and effective regur-
itant orifice area (EROA) over time.” The investigators
oncluded “Depending on the underlying mechanism of MR, Tynamic variations of MRFR and EROA revealed important
ariations of MRSV calculation using single-point and
ime-integral PISA methods.”
c) Calculated MR volume versus qualitative grading of
R. In 89 patients with mild MR, MR volume was 21 
6 (mean 1 SD); in 241 patients with moderate MR, MR
olume was 35  15 ml; and in 441 patients with severe
R, volume was 83 45 (33). The investigators concluded
hat their data demonstrated “the general appropriateness of
he original qualitative grading.”
OMMENT. Their conclusion raises questions; for example,
ow good is “general” appropriate? The range of volumes,
hich is important information, was not provided for each
f 3 grades of severity. Only 1 SD in the severe grade yields
R volumes of 38 to 128 ml; thus, clearly a number of
atients (?%) with severe MR had MR volumes in the
oderate range (30 to 59 ml) (33). Similarly, there must
ave been overlap in mild and moderate MR.
In addition to these 3 studies, an earlier study (34)
howed that the total test-retest variability of assessment of
R by prominent echocardiographers was 24.6  5.2%,
hich consisted of a variability of 7.9  10.2% for acqui-
ition of the studies and of 16.7  8.8% for intrareader
ariability.
The severity of regurgitation is influenced by hemody-
amic conditions, especially by blood pressure at the time of
he recording (35) and also by the timing of atrial contrac-
ion. The American Society of Echocardiography recom-
ends determining quantitative parameters of regurgita-
ion. Quantitation of LV size/volume corrected for body
ize is also very important for determining the severity of
hronic MR and AR.
T3DE is superior to 2DE for assessing severity of
R. In vitro, 3-dimensional VC had better correlation
ith known orifice area compared with 2-dimensional VC
r  0.92, p  0.001 vs. r  0.56, respectively; p  0.01)
36) (Fig. 8). In 61 patients, 3-dimensional VC area
orrelated better with Doppler imaging-derived effective
egurgitant orifice area (EROA) than with 2-dimensional
C (r  0.85, p  0.001 vs. r  0.67, respectively; p 
.001), especially so with eccentric jets (r  0.87, p 0.001
s. r  0.6, respectively; p  0.001) and in moderate to
evere or severe MR versus mild or mild to moderate MR
r  0.80, p  0.001 vs. r  0.18, respectively; p  0.4).
OMMENT. For RT3DE in AS, see the Aortic Valve
tenosis section. RT3DE provides a much better assess-
ent of severe MVD and AVD.
ome good news: increasing performance of MV repair
MVrep). The Society of Thoracic Surgeons database for
V surgery from 2000 to 2007 at 910 hospitals showed that
or isolated MR (n  47,126), the rate of MVrep increased
rom 51% to 69% (p  0.0001) (37). Among 24,404
atients having MV replacement (MVR), the use of me-
hanical valves decreased from 68% to 37% (p  0.0001).
he operative mortality rate for MVR versus MVrep was
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April 20, 2010:1729–42 Year in Valvular Heart Disease.8% versus 1.4%; patients undergoing MVR were older,
ere more severely symptomatic, and were more likely to be
emale and to have a higher incidence of comorbid condi-
ions. For asymptomatic patients, the MVrep operative
ortality rate was 0.6%.
OMMENT. These data must be kept in perspective. a) Besides
perative mortality, major complications still occurred,
hich included reoperation, deep sternal wound infection,
ermanent stroke, and need for dialysis; b) later patient
utcomes and complications, that is, beyond 30 days, are
ot available in the database; and c) the occurrence of major
omplications and the lack of patient outcome data includ-
ng recurrence of MR and of reoperation on long-term
ollow-up is of considerable importance, especially in the
7% of patients who were asymptomatic before surgery.
Modest” rate of progression to need for surgery in
symptomatic patients with severe MR. In a study from
eoul, 286 of 447 patients were treated conservatively.
ndications for surgery developed at a rate of 5% per year
24  3% at 5 years and 33  4% at 7 years) (38).
OMMENT. This rate is similar to that described in the
ienna Study in which it was 6% per year (22  4% at 4
ears and 35  6% at 6 years) (39).
arly surgery for all asymptomatic patients with severe
R due to MV prolapse and/or flail MV? The same
onrandomized prospective study from Seoul of 161 pa-
ients, age 50  15 years, undergoing early MVrep were
ompared with 286 patients, age 51  15 years, not having
arly surgery (39). Comparison of the outcome data was
resented only in the 127 propensity-matched patients in
ach group. The end point of the study was a composite of
perative mortality, cardiac death, repeat MV surgery, and
ospitalization for HF but did not include all-cause mor-
Figure 8 Relationship Between EROA and VC
Effective regurgitant orifice area (EROA) and vena contracta (VC) diameter with 2-d
and between EROA and 3-dimensional VC area (right). Reproduced with permissioality. There were no operative deaths. The event-free 4urvival rate at 7 years was 99  1% in the operated-on
roup and 85  4% (p  0.007) in the conventional group;
% of patients were lost to follow-up. The actuarial 7-year
ardiac mortality was 0% in the operated-on group and 5 
% in the conventional group (p  0.008); 2 patients in the
perated-on group required repeat MV surgery.
In the whole early surgery group (i.e., not just propensity
atched), there were 7 (4.3%) of 161 noncardiac deaths; the
auses of death were not presented. There were 12 (4.2%) of
68 noncardiac deaths in the conventional group; causes of
eath were malignancy in 6, stroke in 3, infection in 2, and
uicide in 1. In the conventional group of 286 patients, 207 did
ot meet criteria for surgery, and there were 3 sudden deaths (2
ue to endocarditis); 66 became symptomatic, but surgery was
erformed only in 50; 13 asymptomatic patients met criteria
or surgery, but surgery was performed only in 3 patients.
OMMENT. The Seoul study must be kept in perspective.
) Coronary arteriography was not performed in the con-
entional group, and they had major risk factors for CAD.
n the conventional group at the end of 7 years, the actuarial
ardiac mortality rate was only 5% (i.e.,0.7%/year). There
ere 4 sudden deaths and 6 HF deaths. Were all these
eaths due to MR or to other causes such as associated
AD and its complications? b) Surgery was not performed
n 16 patients who had become symptomatic and 10 who
ere asymptomatic but met criteria for surgery.
urgery for papillary muscle rupture (PMR) causing
R. A total of 54 patients, age 70 8 years, were operated
n for PMR producing severe MR from 1980 to 2000 (40).
he rupture involved the posterior papillary muscle in 90%;
1% presented in cardiogenic shock and/or with pulmonary
dema and/or in cardiac arrest. Surgery was performed 6 
7 days after the first symptoms, within the first month in
onal echocardiogram (left)
Little et al. (36).imensi
n from5 (83%) and after the first month in 9 (17%). The
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Year in Valvular Heart Disease April 20, 2010:1729–42ncidence of 1, 2, 3, and left main CAD was 31%, 35%,
6%, and 6%, respectively. LVEF was 0.56  0.13. MVrep
as performed in 13 patients. Four of 6 patients who did
ot undergo CABG died. The 10-year survival rate was 35 
%. Among 44 surgery survivors, the 5- and 10-year survival
ates were similar to those of matched patients with myo-
ardial infarction without PMR (Fig. 9); 68% of patients
ere in New York Heart Association functional class I or II
nd 82% were in Canadian Cardiovascular Society angina
lass I or II.
OMMENT. This is a valuable study. Patients with anterior
MR usually die very rapidly and are not commonly seen at
istant referral centers; in this study, 49 of 54 patients had
osterior PMR. How many of the 5 early deaths (2 during
urgery, 1 on postoperative day 1, and 2 of myocardial rupture)
ere associated with the 5 patients with anterior PMR? Of
mportance, those who survived 30 days had a long-term
urvival similar to that of myocardial infarction without PMR.
his is similar to patients with myocardial infarction and
ardiogenic shock; after revascularization, patients who sur-
ived to 30 days had a long-term survival similar to that of
atients with myocardial infarction without shock (41,42).
ricuspid Regurgitation (TR)
eneficial effects of the MAZE procedure in functional
R. The impact of the MAZE operation on the progres-
ion of mild functional TR was studied in 251 patients with
ild functional TR (grade 2) who had successful mitral
alve (MV) procedures for rheumatic disease (43). At
ollow-up of 62.6  39.8 months, “significant” TR in-
reased from 5.2% to 16.4% (p  0.01). Multivariate
nalysis for progression of TR included older age, rheumatic
Figure 9 Late Survival of Operative Survivors of PMR
Ten-year survival in operative survivors for papillary muscle rupture (PMR) is
shown in red and that of patients without PMR surviving acute myocardial
infarction (MI) is shown in blue. Reproduced with permission from Russo
et al. (40).tiology of MVD, and no MAZE operation (adjusted Aazard ratio: 7.90; 95% confidence interval: 1.90 to 32.86).
f 73 patients with pre-operative atrial fibrillation who
nderwent a MAZE procedure, normal sinus rhythm per-
isted in 87.7% at 47.2  26.8 months of follow-up.
atients who did not undergo a MAZE procedure had a
uch higher incidence of significant TR (p  0.01).
OMMENT. Data on tricuspid annular size, which is an
mportant determinant of TR, were not presented.
0-year results of surgery. From 1974 to 2005, 328
atients, age 51.3  13.6 years, 82.6% of whom were
omen, had surgery for rheumatic tricuspid valve disease
44). Actuarial survival rates at 10, 20, and 30 years were
1.8  2.8%, 38.4  3.1%, and 12.1  4.4%, respectively.
nfective Endocarditis (IE)
008 focused update of the American College of Cardi-
logy/American Heart Association 2006 guidelines for the
anagement of patients with valvular heart disease (45).
OMMENT. The only change was to incorporate into the
006 guidelines changes so that the recommendations for
ntibiotic prophylaxis for the prevention of infective endo-
arditis are identical to those of the 2007 American Heart
ssociation recommendations.
uropean Society of Cardiology’s Guidelines on
he Prevention, Diagnosis, and Treatment of IE
New Version 2009) (46).
ospital mortality from 2000 to 2005 is still high. In the
nternational Collaboration on Endocarditis Prospective Co-
ort Study of 3,284 patients, the hospital mortality rate was
7.7% (47). Predictors of mortality are shown in Table 1.
here were small differences in the data from different
ontinents.
nfective Endocarditis: 2000 to 20052,781 Patients, 58 Hospitals in 25 Countries):redictors of Hosp al Mor ity
Table 1
I fective Endocarditis: 2000 o 2005
(2,781 Patients, 58 Hospitals in 25 Countries):
Predictors of Hospital Mortality
Odds Ratio
95% Confidence
Interval
Increased risk
Prosthetic heart valve 1.47 1.13–1.90
Increasing age 1.30 1.17–1.46
Pulmonary edema 1.79 1.39–2.30
Staphylococcus aureus infection 1.54 1.14–2.08
Coagulase negative
Staphylococcal infection 1.50 1.07–2.10
Mitral valve vegetation 1.34 1.06–1.68
Paravalvular complications 2.25 1.64–3.09
Decreased risk
Streptococcus viridans infection 0.52 0.33–0.81
Surgery 0.61 0.44–0.83dapted from Murdoch et al. (47).
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April 20, 2010:1729–42 Year in Valvular Heart Diseaseranscatheter Valve Therapy (TVT)
xtended application of percutaneous pulmonary valve
PV) implantation. Percutaneous PV implantation was
uccessfully performed in 13 patients, age 14.3 years, who
ad severe PV regurgitation after repair of tetralogy of
allot using right ventricular outflow tract patch (48). There
ere significant (p  0.05) reductions of right ventricular
ressure, right ventricle–pulmonary artery gradient and
ncrease in pulmonary artery diastolic pressure. Follow-up at
months showed no deleterious results.
uropean System for Cardiac Operative Risk Evaluation
EuroSCORE) overestimates risks of AVR. a) A total of
,177 patients, age 68  14.7 years, underwent AVR from
000 to 2006 in Rochester, Minnesota. The overall opera-
ive mortality rate was 2.5% (49). The additive and logistic
uroSCORE had predicted operative mortality rates of 6.9
.4% and 10.9  12.7%.
b) A total of 1,545 patients, age 67.1  12.9 years,
nderwent isolated AVR in Heidelberg, Germany, from
994 to 2006 (50). The 30-day mortality rate was 2.2%, and
he EuroSCORE additive and logistic had predicted oper-
tive mortality rates of 8.3% and 14.8%, respectively; 71
atients at very high risk had a zero mortality rate, whereas
he EuroSCORE had predicted a risk of 11% to 20%.
OMMENT. Two earlier studies had also documented Euro-
CORE overestimates of operative mortality rates in val-
ular heart disease (51,52).
utcomes of patients referred for TVT for severe
S. Ninety-two patients, age 81  7 years, were referred
or percutaneous TVT for severe AS (AVA 0.6  0.2 cm2
ot corrected for body surface area); LVEF was 0.46 0.16
53). Under the REVIVAL (Transcatheter Endovascular
mplantation Of Valves) study protocol, patients had TVT
f they were not candidates for surgical AVR. Nineteen had
urgical AVR with a zero operative mortality rate, and 18
ad percutaneous AVR with hospital/30-day mortality rate
f 5%; the incidence of post-operative complications was
lmost identical in both groups. Nine (47%) of 19 who were
eferred for balloon aortic valvuloplasty died. The most
ommon reasons for no intervention included death while
waiting definitive treatment (n  10 [28%]).
ajor MV injury after TVT for severe AS. An 88-year-
ld symptomatic man with severe AS had TVT with a
6-mm SAPIEN valve (Edwards Lifesciences LLC, Irvine,
alifornia) (54). The final valve position was suboptimal,
eing “slightly” low, with ventricular aspect of the stent
butting the anterior leaflet of the MV. The patient devel-
ped MR and AR, and 11 months later, he presented with
E and had 13  8-mm ruptured anterior mitral leaflet,
evere MR, and mild to moderate AR. At reoperation, the
V was repaired, the percutaneous valve was removed and
howed “coccal bacteria”; AVR was performed. The post-
perative course was prolonged and complicated. fore valve: 30-day outcome European Multicenter Registry.
total of 646 patients, age 81  6.6 years, with severe AS
AVA 0.6  0.2 cm2, EuroSCORE 23.1  13.8%), had a
hird-generation (18-F) Core Valve ReValving System
laced. Thirty days after the procedure, mean AV gradient
ad decreased from 50.4  16.9 mm Hg to 3.2  5.2 mm
g. All-cause death was 8%, CV death was 5.9%,
rocedure-related death was 4.2%, stroke or myocardial
nfarction was 9.3% (55).
OMMENT. The prosthetic heart valve (PHV) area was not
resented.
agnetic resonance imaging for coronary sinus great
ardiac vein (CS-GCV). In 31 participants (24 volunteers
nd 7 patients, 15 men; 42  19 years), the CS-GCV was
ocated behind the left atrium at a minimum distance of 8.6
.9 mm from the MV annulus. In 80% of the participants, the
eft circumflex coronary artery crossed the CS-GCV inferiorly
etween the CS-GCV and the MV annulus (56).
OMMENT. Similar data were previously obtained using
ultislice computed tomography (57,58).
ovel device for percutaneous MVrep. In 8 Yucatan pigs,
device consisting of helical stainless steel screws connected
y a biocompatible tether was placed by implanting the
elical screws directly into the myocardium at the posterome-
ial MV annulus. The device was inserted from the internal
ugular vein and performed at Advanced Preclinical services
Coon Rapids, Minnesota) (59). This procedure is intended
or possible use in ischemic MR. Immediately after percuta-
eous MVrep, there were reductions of the MV annulus by
9.7  0.1% (p  0.003) and an 18.8  0.1% reduction of
nteroposterior dimension (p  0.0001). These reductions
ere maintained at 30 and 90 days, at which time there also
as reduction of the commissure dimension (p  0.01).
trial transcatheter approach for MV valve-in–valve
mplantation. Nine adult sheep underwent MVR with a
HV with a 25-mm bioprosthesis. After weaning from
ardiopulmonary bypass, the valve-in-valve implantation
as performed off-pump using an antegrade transatrial
pproach. A transcatheter 23-mm pericardial prosthesis was
mplanted within the conventional bioprosthesis (60). The
ean transvalvular gradient was 4.6  1.0 mm Hg; only 2
heep had mild or moderate MR.
ransapical MV stent implantation. Ten pigs underwent
ransapical off-pump MV stent implantation (61), after
hich hemodynamics were “normal”; TEE showed trace
R in 7 and mild MR in 3; LV angiography showed mild
R in 1.
OMMENT. These 3 studies are initial experimental feasi-
ility studies.
rosthetic Heart Valves
hich valve type (mechanical vs. bioprosthesis) for AVR
n “older” patients? . . . bioprosthesis. a) Medicare data
rom 1,199 U.S. hospitals from 1991 to 2003 shows
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Year in Valvular Heart Disease April 20, 2010:1729–42uperiority of bioprosthesis compared with mechanical valve
62) (Table 2).
b) Data from 3,934 patients who underwent primary
VR procedures were analyzed using microsimulation tech-
ique (63). The microsimulation-calculated techniques for
urvival from the Netherlands were validated both internally
nd externally. Life expectancy after AVR in studies from 2
ountries were compared with that of the population. From
countries, 27% of patients had mechanical valves, their
ean age at implantation was 58 years, the mean follow-up
as 8.5 years, and 73% had bioprosthetic heart valves with
ean age at implantation of 70 years and a mean follow-up
f 6.1 years. Life expectancy after AVR is lower than in the
eneral population, especially in the younger age group (Fig. 10).
or patients older than 60 years, event-free life expectancy
as better with a bioprosthesis. For a 60-year-old man,
omparing bioprosthesis and mechanical valves, simulated
ife expectancy was 11.9 and 12.2 years, event-free life
xpectancy was 9.8 and 9.3 years, and reoperation-free life
xpectancy was 10.5 and 11.9 years, lifetime risk of reop-
edicare Data for Aorticalve Replacement: 1991 to 2003Table 2 Medicare Data for AorticValve Replacement: 1991 to 2003
Bioprostheses vs. Mechanical Valves
Hazard Ratio
95% Confidence
Interval
Death 0.97 0.95–0.98
Readmission for
Hemorrhage, stroke,
embolism
0.9 0.88–0.92
Death or reoperation 0.97 0.96–0.98
Reoperation 1.25 1.16–1.35
Incidence rates
Death vs. reoperation 20 greater
Complications vs. reoperation 10 greater
ioprosthesis: n 111,151; age 76.7 5.9 years; mechanical valve: n 195,903; age 74.7 6.0
ears. Adapted from Schelbert et al. (62).
Figure 10 LE After Aortic Valve Replacement
Life expectancy (LE) with mechanical prosthesis (MP) and bioprosthesis (BP) in the
LE of “normal” US, BC, and United Kingdom (UK) populations. In the younger patie
time of valve implantation increases. Reproduced with permission from van Geldorration was 25% and 3%, lifetime risk of bleeding was 12%
nd 41%, respectively (Fig. 11).
OMMENT. This is another valuable study using micro-
imulation techniques from van Geldorp et al. (63) The
reviously described 2 studies demonstrate better survival
ith a bioprosthesis compared with a mechanical prosthesis.
ost strokes with mechanical PHV are hemorrhagic.
ver a 10-year period, 89 consecutive patients (64) were
ospitalized for stroke (WHO MONICA criteria for stroke
egisters) (65) 90 days after mechanical valve replacement
49 AVR; 33 MVR, 7 AVR  MVR). Determination of
he cause was based on cranial computed tomography or
agnetic resonance imaging. The frequency of each etio-
d States (US) and British Columbia (BC) is lower compared with aged-matched
e difference is large, but the gap narrows considerably as patients age as the
l. (63).
Figure 11 Risks of Bleeding and
Reoperation After Aortic Valve Replacement
Lifetime risks of bleeding and reoperation (red and blue bars) after implantation of
mechanical prosthesis (MP) and bioprosthesis (BP) depending on age at the time
of valve implantation. Bleeding risk with MP (green line) compared with BP (blue
line) widens as patient age increases. Reproduced with permission from van Gel-
dorp et al. (63).Unite
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April 20, 2010:1729–42 Year in Valvular Heart Diseaseogic factor is shown in Table 3. The most frequent cause
as hemorrhagic (n  69; 77.5%); the international nor-
alized ratio ranged from 1.8 to 5. In only 2 patients
2.3%), the cause was related to the prosthesis.
OMMENT. Thought provoking. All such patients should
ave appropriate imaging techniques for initiation of proper
reatment.
oss principle: systematic review and meta-analysis. A
ystematic review (66) of 39 reports published from January
000 to January 2008 on outcomes was presented. For
dults, it included data from 17 publications comprising
,749 patients (Table 4). The authors’ conclusions included
he following: 1) this procedure is almost exclusively used in
hildren and young adults; 2) “noteworthy is the variability
etween studies in autograft and RVOT (RV outflow tract)
tructural and nonstructural valve deterioration rates, caus-
ng increasing variability in reported freedom from these
vents by the end of the first postoperative decade”; and 3)
durability limitations become apparent by the end of the
rst postoperative decade, in particular in younger patients.”
OMMENT. A useful study from Takkenberg et al. (66).
auses of Stroke Afterechanical Prosthe ic Heart Valve (n  89)Table 3 Causes of Stroke Aft rMechanical Prosthetic Heart Valve (n  89)
Bleeding 69 (77.5%)
Small 42
Intermediate 24
Massive 3
Ischemia 20 (22.5)
Nonembolic 7
Embolic 13
Cardioembolic 6
PVE 4
Non-PVE 2
Atherothrombotic 1
alues are n (%) or n. Adapted from Piper et al. (64).
PVE  prosthetic valve endocarditis.
eta-Analysis of the Ross Principle17 Adult Series; n  1,749)Table 4 M ta-Analy i of the Ross Principle(17 Adult Series; n  1,749)
Outcome Estimates (% per yr)
Mean 95% CI
Early mortality 3.24 1.47–6.58
Late mortality 0.64 0.32–1.26
SUUD 0.21 0.05–0.93
Autograft (SVD/NSVD) 0.78 0.43–1.40
RVOT (SVD/NSVD) 0.55 0.26–1.17
TE/BL/VT 0.36 0.15–0.89
Autograft endocarditis 0.26 0.07–0.92
RVOT endocarditis 0.20 0.04–0.92
dapted from Takkenberg et al. (66).
CI  confidence interval; NSVD  nonstructural valve deterioration; RVOT  right ventricular
utflow tract; SUUD sudden unexpected unexplained death; SVD structural valve deterioration;
E/BL/VT  thromboembolism, bleeding, and valve thrombosis.ery wide range of “normal values” of porcine mitral
ioprostheses. A total of 240 patients who were considered
o have “normal” Carpentier-Edwards Duraflex porcine
ioprosthesis were evaluated (67). Of these, 178 (74%) had
TE Doppler imaging performed within the first week after
VR; complete hemodynamic data were available for 198
atients. For any given PHV size (range 25 to 32, there was
wide range of mean PHV gradient and PHV areas (cm2
nd cm2/m2) (Fig. 12).
OMMENT. Valuable and important study. Assuming that
ignificant endothelialization and/or tissue in-growth had
ot occurred within 1 week of implantation, these data show
hat all PHVs of the same size, as stated by the manufac-
urer, do not have the same effective orifice area (valve size)
hen implanted in patients.
ery early structural valve deterioration of the bioprosthesis.
f 122 Medtronic Mosaic porcine valves implanted from
001 to 2005 for AVR, 4 developed SVD (severe stenosis)
ecessitating PHV replacement at 3, 14, 19, and 44 months
Figure 12 Mitral Valve Gradient and
Valve Area for Porcine Bioprosthesis
Carpentier-Edwards Duraflex “normal” porcine mitral bioprosthesis sizes 27 to
35. Patient heart rate 100 beats/min. n  218. Mean mitral valve gradient
(A) and valve area effective orifice area (EOA) by conventional (CON) equation
(B). Error bars shown are mean  2 SD. Reproduced with permission from
Blauwet et al. (67).
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Year in Valvular Heart Disease April 20, 2010:1729–4268). “All 4 patients were aged more than 68 years at time
f implant.”
OMMENT. Even in older patients, structural valve deteriora-
ion can occur very early after porcine PHV implantation.
alve Prosthesis-Patient Mismatch (VP-PM)
ncreases late mortality? a) After AVR. Yes. The index
HV area was determined in 2,576 patients (69). “After
djustment for other risk factors” at 12 years, severe VP-PM
as associated with increased overall morality (p  0.03)
nd CV mortality (p  0.0006) (Fig. 13). Subgroups
howed that mortality was increased in those younger than
0 years (p  0.002) and also those with a body mass index
f 30 kg/m2 (p  0.006); moderate VP-PM was associ-
ted with increased mortality in patients with LVEF 0.50
p  0.01).
OMMENT. Although the mortality in patients 70 years of
ge and older and with a body mass index 30 kg/m2 was
ot significantly higher with severe VP-PM, the number of
atients at risk were very few: 19 and 16, respectively, at the
tart of the study and 1 and 2 patients, respectively, at 12
ears of follow-up.
) After MVR. No, but possibly yes. A total of 2,440
atients had MVR between 1982 and 2002. PHV areas
ere divided into 3 subgroups of VP-PM. No subgroup was
redictive of overall mortality, late mortality, or early mortality
70). However, pulmonary hypertension influenced mortality
y severity of VP-PM (p  0.03), and there was “an inter-
ction between pulmonary hypertension and mild to moderate
Figure 13 Survival With VP-PM
Severe valve prosthesis–patient mismatch (VP-PM) (orange line) is associated wit
cardiovascular deaths (B). Brown line  mild VP-PM; green line  moderate VP-Pp  0.023) and severe (p  0.03)” VP-PM.OMMENT. Mitral VP-PM can cause pulmonary hyperten-
ion. Missing data (on LV end-diastolic and mean left atrial
ressures, and pulmonary vascular resistance) both pre- and
ost-MVR would have allowed for a proper understanding
f the role of LV diastolic dysfunction, VP-PM, and
ulmonary vascular disease in pulmonary hypertension,
hich was a predictor of mortality.
eprint requests and correspondence: Dr. Shahbudin H. Ra-
imtoola, University of Southern California, 1200 North State
treet, Old GNH 7131, Los Angeles, California 90033. E-mail:
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